Dasatinib plus quercetin is a drug combination studied as a senolytic, meant to kill senescent cells selectively. Dasatinib is a kinase inhibitor approved for certain leukemias; quercetin is a plant flavonol. In old mice a single dose, and in progeroid mice periodic doses, were given rather than continuous treatment. Source: Zhu et al., Aging Cell (2015)
Dasatinib + quercetin has been studied in 309 papers since 2015: 15 trials and 13 observational studies in people, 206 in animals, 34 in cells, 34 reviews; 97 in the past year. Its furthest trials in people are at phase 2/3. The newest story, Oct 2, 2026: “Dasatinib and quercetin reduce liver fibrosis in a phase-2 MASH trial”.
Dasatinib + quercetin reduces cellular senescence in human cells and senescence-associated secretory phenotype in humans across independent labs; other results show unchanged senescence in mice or increased senescence in cells. Ten registered trials concern aging; across all uses, two trials ended over a year ago without posted results or linked papers. Some authors have company affiliations, and papers declare company ties.
637 findings in 252 papers from 2015 to 2026, 39 of them since April 2026
CWMH
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
About aging: trials about aging, of every trial that tests the drug for any use.
No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
124 independent labs in 27 countries
28 findings against
18 trials, 11 about aging, 1 with no results posted
↑up: Improves Montreal Cognitive Assessment2 points (95% CI: 0.1, 4.0)
Trial12 people12 weeks
Older adults; older adults with slow gait and mild cognitive impairment
GSA 2024 abstract, Dec 31, 2024
What did studies of Dasatinib + quercetin find?
349
Studies of Dasatinib + quercetin measured 349 outcomes; the most studied are cellular senescence (95 studies), senescence-associated secretory phenotype (SASP) (27) and inflammation (22).
Cellular senescence
↓downin mice49↓downin human cells17↓downin rats12↓downin cells4+11−62%
95 studies
Dasatinib + quercetin decreases cellular senescence in humans (NES −1.4).
“Overall, senolytic treatment led to a significant decreased expression of senescence gene sets in the D + Q group.”
Dasatinib + quercetin decreases cellular senescence in humans (fibrotic MASH).
“Single-nucleus RNA sequencing demonstrates decreased senescence and fibrotic gene signatures and reduced fibrogenic cell populations in the D + Q group.”
Dasatinib + quercetin inhibits cellular senescence in irradiated mice.
“treatment with the senolytic combination of dasatinib and quercetin (D/Q) alleviated DNA damage, inhibited excessive autophagy, and suppressed the GATA4-NF-κB pathway in irradiated mice”
Dasatinib + quercetin decreases cellular senescence in mice (high-fat-diet-induced obesity).
“Dasatinib and quercetin, two established senolytic agents, were co-encapsulated into uPAR-targeted hybrid nanoparticles to selectively eliminate senescent cells”
↓downin mice12↓downin human cells6↓downin cells2↓downin humans2+4
27 studies
Dasatinib + quercetin decreases senescence-associated secretory phenotype (SASP) in humans (symptomatic AD (SToMP)).
“plasma inflammatory markers—including factors of senescence associated secretory phenotype (SASP)—decreased following treatment, a trend that was similarly observed in STAMINA.”
Human trialsymptomatic AD (SToMP)plasma12 weeksn = 5
Dasatinib + quercetin decreases senescence-associated secretory phenotype (SASP) in humans.
“Plasma IL-1α, −2, −6, and − 9 and Matrix Metalloproteinases (MMP)-2, −9, and −12 were significantly lower 11 days after than before the 3 days of D + Q administration”
Dasatinib + quercetin decreases senescence-associated secretory phenotype (SASP) in human fetal lung explants exposed to cannabinoids and nicotine.
“The addition of senolytics, Dasatinib and Quercetin (D + Q), reduced the senescence-associated secretory phenotype (SASP), such as IL-6, IL-8, M-CSF, MCP-3, MIP-1β, TNFα, MIP-3β, and TSLP”
Cellsin human fetal lung explants exposed to cannabinoids and nicotinelung
Dasatinib + quercetin decreases senescence-associated secretory phenotype (SASP) in mice following fracture surgery.
“we also observed reduced levels of proinflammatory senescence-associated secretory phenotype factors in circulation, following fracture surgery, in mice treated with D/Q.”
↓downin mice12↓downin rats3↓downin animals2↓downin human cells2+4
22 studies
Dasatinib + quercetin decreases inflammation in humans.
“Transcriptomic analysis of RNA isolated from PBMC samples revealed baseline to post-treatment downregulation of seven of the 19 inflammatory related genes included in the CTRA transcriptomic stress profile.”
Dasatinib + quercetin decreases inflammation in mice following orthopedic surgery.
“This reduction in senescent cell accumulation was correlated with reduced surgery-induced neuroinflammation, as evidenced by decreased glial cell activity.”
Dasatinib + quercetin improves cognitive function in PS19 mice.
“D + Q-treated PS19 mice exhibit enhanced cue-associated cognitive performance in the tracing fear conditioning test compared to the vehicle-treated littermates”
Dasatinib + quercetin improves cognitive function in TBI mice.
“Behavioral testing at 18 weeks after TBI further revealed that senolytic therapy significantly rescued defects in spatial reference memory and recognition memory, as well as depression-like behavior in TBI mice.”
Dasatinib + quercetin improves physical function in participants with stable IPF.
“Specifically, 6MWD, 4-m gait speed, chair-stands, and SPPB score were significantly improved when assessed one week after the completion of the drug administration (p <.05 all).”
Human trialin participants with stable IPF3 weeksn = 14
Dasatinib + quercetin improves physical function in humans (idiopathic pulmonary fibrosis) (p < .05).
“Physical function evaluated as 6-min walk distance, 4-m gait speed, and chair-stands time was significantly and clinically-meaningfully improved (p < .05).”
Dasatinib + quercetin improves physical function in PF patients.
“A preliminary study on PF patients demonstrated that the combination therapy of the anti-senescence drugs dasatinib and quercetin improved physical functional indicators.”
Dasatinib + quercetin improves physical function in patients with IPF.
“A first-in-human, open-label, pilot study of the senolytic combination of dasatinib and quercetin (DQ) in patients with IPF showed improved physical function and mobility.”
Dasatinib + quercetin improves physical function in senescent cell-transplanted young mice and naturally aged mice.
“intermittent oral administration of senolytics to both senescent cell-transplanted young mice and naturally aged mice alleviated physical dysfunction”
Animalsin senescent cell-transplanted young mice and naturally aged mice
Dasatinib + quercetin decreases oxidative stress and ROS signaling in doxorubicin-treated human cardiac organoids.
“Treatment with D+Q reversed these effects, reducing oxidative stress and senescence markers, alleviating SASP, and restoring hCardioids viability and function.”
Cellsin doxorubicin-treated human cardiac organoids
Dasatinib + quercetin decreases oxidative stress and ROS signaling in heat stressed young adult and aged mice (P < 0.01).
“All the cognitive deficits and other syndromes that occurred in young adult HS mice or in aged HS mice were significantly attenuated by D & Q therapy (P < 0.01).”
Animalsin heat stressed young adult and aged mice3 consecutive days every 2 weekshippocampus10-week periodmales
“Though these outcomes would not have survived corrections for multiple comparisons, there were significant post-treatment increases in the following multifunctional biofluid proteins: plasma fractalkine and MMP-7, and CSF IL-6; other analytes that displayed trends toward change at P < 0.1 were plasma eotaxin and VEGF ( and Supplementary Table 2”
“In CSF, thymus- and activation-regulated chemokine (TARC), IL-17A, I-TAC, eotaxin-2, eotaxin and MIP-1α levels decreased and IL-6 levels increased from baseline to post-treatment.”
Dasatinib + quercetin increases IL-6 in humans (early-stage symptomatic AD) (t(4) = 3.913, P = 0.008).
“CSF levels of interleukin-6 (IL-6) and glial fibrillary acidic protein (GFAP) increased (t(4) = 3.913, P = 0.008 and t(4) = 3.354, P = 0.028, respectively)”
Human trialearly-stage symptomatic ADoralcerebrospinal fluid12-weekn = 5
“senolytic treatment in aged burn mice reduced cellular senescence, demonstrated by a 4.4-fold decrease in senescence-associated beta-galactosidase-positive skin cells to baseline levels”
Dasatinib + quercetin decreases senescent cell burden in mice during PTH treatment.
“Co-administration of the senolytic agents dasatinib and quercetin during PTH treatment reduced senescent cell burden, improved cortical porosity, and mitigated rapid bone loss after PTH discontinuation in aged mice.”
Dasatinib + quercetin decreases senescent cell burden in doxorubicin-treated ovaries.
“Short-term intervention with the classic senolytic combination dasatinib and quercetin (DQ) or fisetin significantly reduced the load of senescent cells in ovaries after doxorubicin treatment.”
Dasatinib + quercetin decreases TNF-alpha in humans.
“The mean percent reduction in TNF-α was significantly different (p = 0.04) than the mean percent change in the Biomarker Control group (mean percent change = 16.8, 95% CI: −1.7, 35.4).”
Dasatinib + quercetin decreases TNF-alpha in humans (at risk of Alzheimer's disease) (-3.0% (95% CI: -13.0, 7.1)).
“Mean percent change in tumour necrosis factor-alpha (TNF-α), a key product of the senescence-associated secretory phenotype (SASP), non-significantly decreased following DQ by -3.0% (95% CI: -13.0, 7.1)”
Human trialat risk of Alzheimer's disease100 mg Dasatinib and 1250 mg Quercetin for two days every two weeks12 weeksn = 12
Dasatinib + quercetin increases bone mineral density in women with highest tertile for T cell p16 mRNA levels (+2.7%, P = 0.004).
“in which D + Q concomitantly increased P1NP (+34%, P = 0.035) and reduced CTx (-11%, P = 0.049) at 2 weeks, and increased radius bone mineral density (+2.7%, P = 0.004) at 20 weeks”
Human trialin women with highest tertile for T cell p16 mRNA levels20 weeksfemales
“Using the SIMOA assays, there were no pre- to post-treatment changes in plasma or CSF protein levels with the exception of a significant increase of GFAP levels in CSF.”
Dasatinib + quercetin decreases liver fibrosis in humans (fibrotic MASH) (47% versus 7%).
“≥1 stage fibrosis improvement without MASH worsening on paired liver biopsies, is achieved in 47% of D + Q-treated participants versus 7% with placebo (P = 0.02)”
Human trialfibrotic MASHliverdasatinib 100 mg per day plus quercetin 1,000 mg per daythree consecutive days per week over 3 weeks, repeated across three 7-week cycles76% malesn = 31
Dasatinib + quercetin decreases telomere length in humans.
“Specifically, we observed a significant decrease in PC DNAm telomere length after the whole treatment (p-value=0.01, see ), which was even more significant after adjusting by age (p-value=4.4·10−4, see ).”
Studies link Dasatinib + quercetin with 5 measures, most often atrial fibrillation (1 study), stem cell differentiation (1) and CD8 T cell immunodominance (1).
Atrial fibrillation
↓downin mice1
1 study
Dasatinib + quercetin lowers the risk of atrial fibrillation in irradiated mice.
“These improvements resulted in the reversal of atrial structural and electrophysiological remodeling and a marked reduced susceptibility to AF.”
Dasatinib + quercetin is associated with CD8 T cell immunodominance in mice (influenza vaccination prior to infection).
“However, we observed altered CD8 T cell immunodominance and increased serum total PR8 (whole flu) IgG antibodies in D + Q treated vaccinated aged mice during infection.”
Dasatinib + quercetin is associated with gut microbiota in type 2 diabetic osteoporosis mouse model.
“The results demonstrated that D + Q reshaped gut microbiota, resulting in increased short-chain fatty acid producers (Lachnospiraceae and Bacteroides) and decreased proinflammatory bacteria (Mucispirillum)”
Animalsin type 2 diabetic osteoporosis mouse model
Tiny carriers delivered two cell-clearing drugs in two mouse models, improving survival and avoiding blood-cell side effects associated with dasatinib given without…Tiny carriers delivered two cell-clearing drugs in two mouse models, improving survival and avoiding blood-cell side effects associated with dasatinib given without carriers.
A nine-month randomized experiment in 12-month-old mice compared exercise (11 mice), two drugs (15), both (16) and natural aging (12); the interventions improved heart…A nine-month randomized experiment in 12-month-old mice compared exercise (11 mice), two drugs (15), both (16) and natural aging (12); the interventions improved heart performance.
The senolytic combination improved liver fibrosis without disease worsening in nearly half of treated participants while lowering cellular senescence markers.The senolytic combination improved liver fibrosis without disease worsening in nearly half of treated participants while lowering cellular senescence markers.